Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628051 | 0.83 | ALDH1A1 (0.33) | EGLN1ALDH1A1TSHR | |
| SCHEMBL5212003 | 0.79 | GAA (0.58) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL3404242 | 0.79 | MGAM (0.41) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL8804853 | 0.78 | GAA (0.52) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL6631579 | 0.78 | MGAM (0.39) | MAPTGAAMGAMSIMGAM2 | |
| Butane SCHEMBL1924654 | 0.76 | FAAH (0.39) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL13074661 | 0.76 | GAA (0.38) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL28290300 | 0.74 | MGAM (0.50) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL28290424 | 0.74 | MGAM (0.50) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL1806737 | 0.73 | GAA (0.39) | MAPTGAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022259993-A1 | PPARα TRANSCRIPTION ACTIVATOR AND PHARMACEUTICAL USE THEREOF | 国立大学法人大阪大学 | 2022-12-15 | — | — | WO | disclosed |
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-22 | — | — | US | disclosed |
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-22 | — | — | US | disclosed |
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-22 | — | — | US | disclosed |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| EP-3010903-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2016-04-27 | — | — | EP | disclosed |
| EP-3010905-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202580-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014202528-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014202580-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | OXER1, AK2, GPR119 | MAPT 3467/4885GAA 2109/4885MGAM 3200/4885 |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | AK2, PRKAA2, PRKAA1 | MAPT 3784/4885GAA 1950/4885MGAM 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.